QYUNS-B (02509) has reached a global exclusive licensing agreement with Roche for QX031N.

QYUNS-B (02509) announced on October 28, 2025 that the company has reached a global exclusive cooperation and licensing agreement with F. Hoffmann-La Roche Ltd. As per the agreement, the group grants Roche the global exclusive rights to develop, manufacture, and commercialize QX031N (product). The company will receive a one-time, non-refundable, and non-offsettable upfront payment of 75 million US dollars, and will be eligible to receive up to 995 million US dollars in milestone payments related to product development, regulatory approval, and commercialization, as well as gradient royalties on potential future product sales.